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Pharmaceutical benefits scheme cost recovery
Abstract
Since the beginning of 2010 the Australian Government has applied cost recovery to the listing process of
the Pharmaceutical Benefits Scheme (PBS). Drug companies seeking to list their drugs on the PBS or
vaccines on the National Immunisation Program pay a fee at two key points - upon lodgement of the
application and at the pricing stage. The lodgement fee relates to the evaluation work of the
Pharmaceutical Benefits Advisory Committee (PBAC) and all of its supporting administrative functions.
The pricing fee relates to the pricing work of the Pharmaceutical Benefits Pricing Authority and its
supporting functions. Companies that want an independent review of a PBAC recommendation to not list
a drug on the PBS will also pay. The fees are not trivial - $119 500 for a major PBAC evaluation, $25 000
for a complex 'pricing' and $119 500 for an independent review. Hardly spare change, even for a
pharmaceutical company. So what is the purpose of the cost recovery scheme and what are the likely
consequences?
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Editorial
Pharmaceutical Benefits Scheme cost recovery
Glenn Salkeld, Head, School of Public Health, University of Sydney, New South Wales
The stated purpose is to recover the cost of the services

Key words: cost-effectiveness, drug industry.
(Aust Prescr 2011;34:62–3)

Since the beginning of 2010 the Australian Government has
applied cost recovery to the listing process of the Pharmaceutical
Benefits Scheme (PBS). Drug companies seeking to list their
drugs on the PBS or vaccines on the National Immunisation
Program pay a fee at two key points – upon lodgement of the
application and at the pricing

stage.1

The lodgement fee relates

provided (evaluation and pricing) and to promote efficient
allocation of resources.1 Depending on your point of view it
is either an attempt to gouge the pockets of industry or a 'fair
cop guv'. After all, the pharmaceutical industry does very nicely
from PBS price subsidies, and so does the Australian public.
All parties benefit from the PBS – the key question is whether
cost recovery threatens the very process that has delivered safe,

to the evaluation work of the Pharmaceutical Benefits Advisory

timely and affordable access to prescribed medicines for all

Committee (PBAC) and all of its supporting administrative

Australians.

functions. The pricing fee relates to the pricing work of the

Some of the early response to the cost recovery proposal

Pharmaceutical Benefits Pricing Authority and its supporting

has been reminiscent of the reaction when the PBAC started

functions. Companies that want an independent review of

to assess the cost-effectiveness of drugs (National Health

a PBAC recommendation to not list a drug on the PBS will

Amendment Bill 1987). It was feared that the extra cost of

also pay. The fees are not trivial – $119 500 for a major PBAC

preparing submissions would result in Australia missing out

evaluation, $25 000 for a complex 'pricing' and $119 500 for

on new drugs. However, the PBAC cost-effectiveness process

an independent review.2 Hardly spare change, even for a

is designed to reward sponsors with higher prices for drugs

pharmaceutical company. So what is the purpose of the cost

that provide greater clinical benefit than the drugs which

recovery scheme and what are the likely consequences?

are currently available. It does not reward those drugs that
do not confer additional clinical benefit. Without the costeffectiveness requirement the PBS would probably have sunk

In this issue…

under the weight of its own success. It may still do so unless

The cost of the Pharmaceutical Benefits Scheme will always

pharmaceutical expenditure is kept under tight control. There

be a topic for debate, but it is important to know that

are, however, legitimate concerns about cost recovery.

the evaluations of cost-effectiveness are assessed by the

The first concern is that PBS cost recovery may be the straw

independent Pharmaceutical Benefits Advisory Committee.

that will break the camel's back. The pharmaceutical industry

Glenn Salkeld reassures us that the introduction of

is already carrying the load of lower profits, fewer blockbuster

evaluation fees will not compromise this independence.

drugs in the pipeline and the high cost of getting a drug to

Independence is also important when assessing

market. Critics of cost recovery argue that some new drugs

information about medicines. Rosalind Tindale tells us

may never enter the Australian market due to higher costs

where to find independent sources of drug information.

of registration and PBS listing (or face lengthy delays in

Genetic information has changed the way haemochromatosis
is investigated. Andrew St John, Katherine Stuart and
Darrell Crawford review how to make the diagnosis.
The prognosis for patients with HIV has improved, but
regular monitoring and adherence to treatment are

reaching our shores). Those that do will be more expensive (as
companies will pass on the extra cost of PBS listing) and smaller
companies may be driven out of the market. Furthermore, cost
recovery may discourage development of drugs aimed at a
lower volume market.

essential. Tom Turnbull provides advice on how general

Let us get some perspective here. In 2008–09, the Australian

practitioners can assist in management.

Government spent more than $7.679 billion on pharmaceutical

The management of sleep apnoea may also involve a range
of health professionals. Stuart MacKay outlines some of the
treatment options.
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benefits.3 That is taxpayer dollars that not only provide health
benefits to millions of Australians but also contribute directly to
bottom line industry profits. At face value industry can afford
the extra impost of cost recovery. It is unlikely that new drugs
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will be prevented or delayed in reaching the Australian market.

Regulations 20092 an exemption may be granted in respect

The Australian pharmaceutical market is a competitive one

of orphan drugs, the temporary supply of drugs or changes

and 'if a company decides not to launch a particular product

to an existing PBS listing. A fee waiver may be granted if 'the

in Australia, then competitors' products come in'.4 If there is

application involves the public interest and payment of the

no competitor then it is possible that a sole manufacturer may

fee would make the application financially unviable'. This may

decide not to introduce a new product to the Australian market.

apply when the patient population is not large enough to make

It is a commercial decision. If cost recovery fees alone swing the

the application financially viable, the product is to be used for

manufacturer's net present value calculation of a new drug from

palliative care or as a paediatric medicine, or for treatment of

a decision to submit (to the Therapeutic Goods Administration

Aboriginal or Torres Strait Islander people.

(TGA) and subsequently to PBAC) to 'not submit', then the case

For any change in policy it pays to be vigilant and monitor

for registration and PBS listing is likely to have been marginal in

any unintended consequences. If experience is anything to

the first place.

go by, the PBAC process will survive. Numerous reviews and

Another concern is that cost recovery may compromise the

a few detractors have not weakened the inherent strength of

independence of the PBAC, because it will be paid by the drug

a legislated process that supports evidence-based decision

companies. This fear appears to be unfounded because the

making.

PBAC has no direct pecuniary interest in the process. All the
income from cost recovery fees goes into consolidated revenue
rather than to the PBAC itself. Neither the Department of Health
and Ageing nor the PBAC would actually see any of the 'cost
recovery' funds. Historically the PBAC has shown itself to be
strongly independent. Since 1998–99 the TGA has operated on
a full cost recovery basis. I have not seen evidence to suggest
that the TGA has been compromised by the introduction of cost
recovery.
It is fair to say that a lot of effort has gone into making the PBAC
process more transparent and responsive to the needs of drug
companies and this preceded the introduction of cost recovery.
The industry's expectations of the process may increase as a
result of the new fees, with an understandable desire for quicker
turnaround of PBAC submissions. Time will tell how the PBAC
responds to the concurrent demands of meeting their legislative
requirements and managing what is the inherently adversarial
nature of negotiating drug prices.
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Of course there are instances when the imposition of the cost

Professor Salkeld has received an honorarium from

recovery fee is not in the public interest. Under the National

Pfizer for teaching a short course on 'cost-effectiveness of

Health (Pharmaceuticals and Vaccines – Cost Recovery)

pharmaceuticals'.

Letters
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which
refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. Letters are usually
published together with their responses or comments in the same issue. The Editorial Executive Committee screens out discourteous, inaccurate
or libellous statements and sub-edits letters before publication. The Committee's decision on publication is final.

Denosumab
Editor, – We welcome being recognised for transparency

We were, however, surprised to read a statement, based on

in supplying Therapeutic Goods Administration (TGA)

a meta-analysis1 that 'denosumab was not associated with

evaluation data to Australian Prescriber to assist in the

a significant reduction in fracture risk in postmenopausal

preparation of the new drug comment about denosumab

women', despite your review having previously described a

(Prolia) (Aust Prescr 2010;33:194).

clinical trial which showed statistically significant reductions
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